Novo’s oral semaglutide outperforms Jardiance in late-stage study
Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a stat...
Continue Reading →
